Distalmotion has grabbed hold of a de novo clearance for its Dexter surgical robot, a system designed for hospitals as well ...

Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, ...

Israeli computational biology company Evogene is looking to the clouds to secure the computational power it needs to develop ...

As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a ...

Kymera Therapeutics is pivoting focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 studies via partnerships. | Kymera Therapeutics is pivoting its focus from ...

The week after seeing its partner Roche cut and run, UCB has reported the failure of its anti-tau antibody bepranemab to improve cognition and function in people with early Alzheimer’s disease. But ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...

Biogen is tapping some top pharma talent to lead its medical efforts. Daniel Quirk, M.D., is the biotech’s new chief medical officer and head of medical affairs. Quirk formerly served as a senior vice ...

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...